^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ATP1B1-NRG1 fusion

    i
    Other names: ATP1B1, ATPase Na+/K+ Transporting Subunit Beta 1, Sodium/Potassium-Transporting ATPase Subunit Beta-1, Sodium-Potassium ATPase Subunit Beta 1 (Non-Catalytic), ATPase, Na+/K+ Transporting, Beta 1 Polypeptide, Sodium Pump Subunit Beta-1, ATP1B, Sodium/Potassium-Transporting ATPase Beta-1 Chain, Sodium/Potassium-Dependent ATPase Beta-1 Subunit, Sodium/Potassium-Dependent ATPase Subunit Beta-1, Beta 1-Subunit Of Na(+),K(+)-ATPase Na, K-ATPase Beta-1 Polypeptide, Adenosinetriphosphatase, NRG1, GGF,
    Entrez ID:
    3084; 481
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. (PubMed, J Natl Cancer Inst)
    PGVs are present in a substantial minority of patients with EOPC. Actionable somatic alterations were identified frequently in EOPC, enriched in the RAS wild-type subgroup. These observations underpin the recent guidelines for universal germline testing and somatic profiling in pancreatic ductal adenocarcinoma.
    Clinical • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NRG1 (Neuregulin 1) • ETV6 (ETS Variant Transcription Factor 6) • ATP1B1 (ATPase Na+/K+ transporting subunit beta 1)
    |
    NTRK1 fusion • NRG1 fusion • ATP1B1-NRG1 fusion • IDH1 R132C
    almost4years
    [VIRTUAL] Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions (AACR 2021)
    There was no shrinkage of afatinib-treated pancreatic PDX tumors.Our results here suggest that seribantumab is effective at reducing tumor growth in preclinical models of gastrointestinal cancers with NRG1 fusions. These data support the use of seribantumab to treat GI and other cancers with NRG1 fusions in the ongoing phase 2 CRESTONE study (NCT#04383210).
    Preclinical
    |
    NRG1 (Neuregulin 1) • SLC3A2 (Solute Carrier Family 3 Member 2) • ATP1B1 (ATPase Na+/K+ transporting subunit beta 1) • EGF (Epidermal growth factor)
    |
    ERBB3 expression • NRG1 fusion • ATP1B1-NRG1 fusion • SLC3A2-NRG1 fusion • APP-NRG1 fusion
    |
    Gilotrif (afatinib) • seribantumab (MM-121)